We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+9.41%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$1.08B
(+126%)
Cap. Flow
+$347M
Cap. Flow
% of AUM
17.97%
Top 10 Holdings %
Top 10 Hldgs %
58.78%
Holding
104
New
42
Increased
25
Reduced
17
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARK Genomic Revolution ETF
ARKG
|
+$80M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$31.3M |
| 3 |
OCDX
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
|
+$24.2M |
| 4 |
Community Health Systems
CYH
|
+$23.5M |
| 5 |
McKesson
MCK
|
+$22.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$23.6M |
| 2 |
The Ensign Group
ENSG
|
+$15.4M |
| 3 |
CTLT
CATALENT, INC.
CTLT
|
+$13M |
| 4 |
HSKA
Heska Corp
HSKA
|
+$11.5M |
| 5 |
RAD
Rite Aid Corporation
RAD
|
+$10.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.91% |
| 2 | Miscellaneous | 40.99% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTLT
26
DELISTED
CATALENT, INC.
CTLT
| $17.2M | 0.89% |
163,114
-116,389
| -42% | -$13M |
|
27
Becton Dickinson
BDX
$51.6B
| $16.6M | 0.86% |
+70,093
| New | +$17.1M |
|
|
BHVN
28
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $16.6M | 0.86% |
242,172
+138,408
| +133% | +$11.2M |
|
29
HCA Healthcare
HCA
$90.5B
| $16.1M | 0.83% |
85,409
+68,655
| +410% | +$12.1M |
|
|
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
| $16.1M | 0.83% |
823,229
-86,479
| -10% | -$1.77M |
|
|
DCPH
31
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $15.5M | 0.8% |
345,717
+99,477
| +40% | +$4.63M |
|
32
CALL
Vertex Pharmaceuticals
VRTX
$137B
| $12.9M | 0.67% |
+60,000
| New | +$13.2M |
|
|
TARO
33
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $12.1M | 0.63% |
164,378
+12,122
| +8% | +$920K |
|
34
Alnylam Pharmaceuticals
ALNY
$31.7B
| $11.4M | 0.59% |
+80,937
| New | +$12.2M |
|
35
Acadia Pharmaceuticals
ACAD
$5.02B
| $10.8M | 0.56% |
+420,000
| New | +$18.5M |
|
36
Humana
HUM
$46.3B
| $10.4M | 0.54% |
+24,839
| New | +$9.92M |
|
|
ITCI
37
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.2M | 0.53% |
300,587
-55,648
| -16% | -$1.93M |
|
38
argenx
ARGX
$64B
| $9.88M | 0.51% |
+35,886
| New | +$11.3M |
|
39
ARK Innovation ETF
ARKK
$6.46B
| $9.84M | 0.51% |
+82,000
| New | +$11.1M |
|
|
MGLN
40
DELISTED
Magellan Health Services, Inc.
MGLN
| $9.76M | 0.51% |
104,700
| – | – |
|
41
Cigna
CI
$73.7B
| $9.67M | 0.5% |
+40,000
| New | +$8.92M |
|
42
MannKind Corp
MNKD
$1.27B
| $8.49M | 0.44% |
+2,165,383
| New | +$8.89M |
|
|
AFMD
43
DELISTED
Affimed
AFMD
| $8.27M | 0.43% |
104,613
+8,142
| +8% | +$529K |
|
44
DexCom
DXCM
$34.3B
| $6.74M | 0.35% |
74,964
+65,072
| +658% | +$6.11M |
|
45
Guardant Health
GH
$21.7B
| $6.14M | 0.32% |
+40,247
| New | +$6.08M |
|
46
Novavax
NVAX
$1.53B
| $6.07M | 0.31% |
+33,473
| New | +$6.67M |
|
47
Natera
NTRA
$47B
| $5.86M | 0.3% |
+57,700
| New | +$6.32M |
|
48
Centene
CNC
$32B
| $5.82M | 0.3% |
+91,120
| New | +$5.64M |
|
|
SRGA
49
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $5.75M | 0.3% |
+87,993
| New | +$6.14M |
|
|
KDMN
50
DELISTED
Kadmon Holdings, Inc.
KDMN
| $5.34M | 0.28% |
1,373,119
-1,035,766
| -43% | -$4.74M |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Eversept Partners held 104 positions worth $1.93B, up 126% from $852M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Eversept Partners deployed $347M of net new capital in Q1 2021, opening 42 new positions and adding to 25 existing holdings. Its largest new stake was ARK Genomic Revolution ETF: 806,932 shares worth $71.6M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
On the sell side, the largest reduction was The Ensign Group, an estimated $15.4M trimmed.
- Eversept Partners's largest Q1 2021 buy was ARK Genomic Revolution ETF: 806,932 shares worth $71.6M.
- Eversept Partners added most to Community Health Systems in Q1 2021, an estimated $23.5M increase.
- Eversept Partners's biggest Q1 2021 reduction was The Ensign Group, cutting an estimated $15.4M.
- Eversept Partners fully exited Sarepta Therapeutics in Q1 2021, selling an estimated $23.6M.
- Eversept Partners's ten largest holdings make up 59% of its $1.93B portfolio in Q1 2021.
- Eversept Partners opened 42 new positions and closed 19 in Q1 2021.
- Eversept Partners's portfolio value rose 126% quarter-over-quarter to $1.93B.
Based on Eversept Partners's 13F filing for Q1 2021, filed 13 May 2021.